天津医药

天津医药 ›› 2017, Vol. 45 ›› Issue (3): 239-243.doi: 10.11958/20161572

• 实验研究 • 上一篇    下一篇

辛通畅络法复方肾苏Ⅱ阻抑局灶节段性肾小球硬化大鼠肾间质纤维化及转化生长因子 β1表达的影响

窦一田， 李翀△， 马鸿杰， 张涛   

  1. 天津中医药大学第一附属医院 （邮编 300381）
  • 收稿日期:2016-12-26 修回日期:2017-01-11 出版日期:2017-03-15 发布日期:2017-03-21
  • 通讯作者: 李翀 E-mail:lc740922@163.com
  • 基金资助:
    国家自然科学基金青年科学基金项目（81403333）； 天津市应用基础与前沿技术研究计划项目（14JCQNJC11400）； 天津市高等学校科技发展基金计划项目 （20130210）； 天津市卫生和计划生育委员会中医中西医结合科研课题项目 （2015102）

The effect of Xintong Changluo complex prescription ShensuⅡ on renal interstitial fibrosis and TGF-β1 expression in FSGS rats

DOU Yi-tian, LI Chong△, MA Hong-jie, ZHANG Tao   

  1. The First Affiliated Hospital of Tianjin University of TCM, Tianjin 300381, China
  • Received:2016-12-26 Revised:2017-01-11 Published:2017-03-15 Online:2017-03-21
  • Contact: LI Chong E-mail:lc740922@163.com

PDF (PC)

3692

摘要： 摘要： 目的 观察辛通畅络法复方肾苏Ⅱ对局灶节段性肾小球硬化 （FSGS） 大鼠肾间质纤维化 （RIF） 进程及转化生长因子 β（ 1 TGF-β1） 表达的影响。方法 48 只健康雄性 SD 大鼠采用随机数字表法分为对照组 12 只和造模组 36只。造模组大鼠采用阿霉素注射法诱发 FSGS 型阿霉素肾病模型， 再采用随机数字表法均分为模型组、 西药组和中药组， 西药组 0.33 mg/100 g 灌服洛汀新混悬液， 中药组 3.5 g/100 g 灌服肾苏Ⅱ， 模型组及对照组灌服等量生理盐水，共 12 周。行 HE 染色、 Masson 染色观察各组肾小管-间质病理形态改变情况， 测定肾小管间质损伤指数和肾小管-间质纤维化指数， 并采用免疫组化 SP 法检测肾小管间质纤维连结蛋白 （FN） 和 TGF-β1相对表达水平。结果 中药组 FSGS 大鼠肾间质纤维化进程延缓， 肾小管-间质损伤指数（1.51±0.80）低于模型组（2.18±0.38）和西药组（1.79±0.24）， 肾小管-间质纤维化指数（2.39±0.13）低于模型组（3.11±0.25）和西药组（2.80±0.41）， 肾间质 FN 相对表达量（14.19±3.06）低于模型组（21.25±3.31）和西药组（18.51±2.29）， TGF-β1 相对表达量（2.64±0.21）低于模型组（6.02±0.12） 和西药组 （3.79±0.46）， 差异均有统计学意义 （均 P＜0.05）。结论 辛通畅络法复方肾苏Ⅱ可延缓 FSGS 大鼠肾间质纤维化进程， 作用机制可能与抑制 TGF-β1表达有关。

关键词: 肾小球硬化症, 局灶节段性, 转化生长因子β1, 肾间质纤维化, 辛通畅络法, 肾苏Ⅱ

Abstract: Abstract: Objective To observe and discuss the effect of the traditional Chinese drug complex prescription ShensuⅡfrom Xintong Changluo therapeutic principle on renal interstitial fibrosis (RIF) and transforming growth factor-β1 (TGF-β1)expresssion in focal segmental glomerulosclerosis (FSGS) model rats. Methods Forty- eight healthy male SD rats were randomly divided into control group (n=12) and modeling group (n=36). Rats of modeling group were injected by doxorubicin hydrochoride for FSGS model. Rats of modeling group were sub-divided into model group, benazepril group and TCM group randomly. In 12 weeks, TCM group was given by intragastric administration of ShensuⅡ (3.5 g/100 g), benazepril group was given by intragastric administration of benazepril suspension (0.33 mg/100 g), control group and model group were given by intragastric administration of same volume of saline. HE /Masson staining was used to observe changes of tubulointerstitial pathomorphology. The degree of injury and fibrosis was measured. The expressions of fibronectin (FN) and TGF- β1 were detected by immunohistochemical SP method. Results The process of renal interstitial fibrosis was slower in FSGS rats of TCM group. Renal interstitial pathological index was 1.51±0.80 in TCM group, which was lower than that of model group(2.18±0.38) and benazepril group (1.79±0.24). The index of renal interstitial fibrosis was 2.39±0.13 in TCM group, which was lower than that of model group (3.11±0.25) and benazepril group (2.80±0.41). The relative expression of FN in renal interstitial was 14.19 ± 3.06 in TCM group, which was lower than that of model group (21.25 ± 3.31) and benazepril group(18.51±2.29). The relative expression of TGF-β1 in renal interstitial was 2.64±0.21 in TCM group, which was lower than that of model group (6.02±0.12) and benazepril group (3.79±0.46). All the differences were statistically significant (P＜0.05).Conclusion Xintong Changluo complex prescription ShensuⅡcan reduce the process of renal interstitial fibrosis in FSGS model rats, which may be related with the inhibiting expression of TGF-β1.

Key words: glomerulosclerosis, focal segmental, transforming growth factor beta 1, renal interstitial fibrosis, Xintong Changluo therapeutic principle, ShensuⅡ